Microcalcifications in Atherosclerotic Plaque

动脉粥样硬化斑块中的微钙化

基本信息

  • 批准号:
    10411607
  • 负责人:
  • 金额:
    $ 15.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-05 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

SUMMARY Human fibroatheroma (FA) cap rupture leads to the formation of an occluding thrombus, myocardial infarction (MI) and sudden death in more than half a million Americans every year. A vulnerable plaque is defined as a positively remodeled lesion, rich in vasa-vasorum, characterized by smooth muscle cell apoptosis, and containing a lipid rich pool with a fibrous cap that is infiltrated by macrophages. The current paradigm is that a cap thickness < 65 µm (thin-cap FA or TCFA) is the key determinant of plaque vulnerability, and rupture occurs when the cap tissue experiences a peak stress greater than 300 kPa. However, there are several other factors that play an important role in the FA cap rupture, including atheroma morphology, biological environment, tissue composition and mechanical forces. Indeed, whether the cap thickness is the single most important criterion predicting plaque vulnerability is unclear, and the underlying mechanisms for atheroma cap rupture are still insufficiently understood. Vascular calcification has emerged among the factors that play an important role in the stability of plaque rupture. For many decades, cardiovascular calcification has been considered as a passive process, accompanying atheroma progression, correlated with plaque burden, and apparently without a major role on plaque vulnerability. Clinical and pathological analyses have previously focused on the total amount of calcification (calcified area in a whole atheroma cross section), and whether more calcification means higher risk of plaque rupture or not. However, this paradigm has been changing in the last decade or so. Recent research has focused on the presence of microcalcifications (µCalcs) in the atheroma, and more importantly on whether clusters of µCalcs are located in the cap of the atheroma. While the vast majority of µCalcs are found in the lipid pool or necrotic core, they are inconsequential to vulnerable plaque. We have also demonstrated to date the existence of thousands of μCalcs primarily in non-ruptured human atheroma caps using µCT imaging, and that they behave as an intensifier of the background circumferential stress in the cap. However, the similar X-ray absorption properties of a thrombus and soft tissue complicates the analysis of μCalcs in ruptured FAs. To overcome this limitation, we have developed a high-resolution contrast-enhanced µCT (CEµCT) approach to investigate whether μCalcs co-localize with the site of FA cap rupture, in cases where an occluding thrombus is formed, followed by myocardial infarction. The working hypothesis is that μCalcs in the FA cap has a major effect on the FA cap rupture threshold. To test this hypothesis we propose to (1) determine the sensitivity and specificity of μCalcs in the FA cap as a key biomarker of fibroatheroma rupture risk in human coronary vessels, and (2) to characterize the increase in FA rupture risk due to μCalcs in the ApoE KO mice. If successful, the proposed study will increase our understanding on vulnerable plaque rupture biomechanics and provide an alternative paradigm for vulnerable plaque that will consider the effect of μCalcs in human atheroma cap rupture risk.
总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Luis Cardoso其他文献

Luis Cardoso的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Luis Cardoso', 18)}}的其他基金

Acquisition of a Verasonics Vantage 256 Research Ultrasound Platform
收购 Verasonics Vantage 256 研究超声平台
  • 批准号:
    10415588
  • 财政年份:
    2022
  • 资助金额:
    $ 15.7万
  • 项目类别:
Acquisition of Colaborative Robot System for Ultrasound Research
采购用于超声研究的协作机器人系统
  • 批准号:
    10798904
  • 财政年份:
    2022
  • 资助金额:
    $ 15.7万
  • 项目类别:
Mechanical Function of Trabecular Bone: Bone Loss Assessment Beyond BMD
小梁骨的机械功能:BMD 之外的骨丢失评估
  • 批准号:
    8630400
  • 财政年份:
    2014
  • 资助金额:
    $ 15.7万
  • 项目类别:
Mechanical Function of Trabecular Bone: Bone Loss Assessment Beyond BMD
小梁骨的机械功能:BMD 之外的骨丢失评估
  • 批准号:
    9236194
  • 财政年份:
    2014
  • 资助金额:
    $ 15.7万
  • 项目类别:
Mechanical Function of Trabecular Bone: Bone Loss Assessment Beyond BMD
小梁骨的机械功能:BMD 之外的骨丢失评估
  • 批准号:
    8829243
  • 财政年份:
    2014
  • 资助金额:
    $ 15.7万
  • 项目类别:
Mechanical Function of Trabecular Bone: Bone Loss Assessment Beyond BMD
小梁骨的机械功能:BMD 之外的骨丢失评估
  • 批准号:
    9044771
  • 财政年份:
    2014
  • 资助金额:
    $ 15.7万
  • 项目类别:
Age Related Bone Loss Assessed by Ultrasound Tomography: Bone Quality Beyond BMD
通过超声断层扫描评估与年龄相关的骨质流失:骨质量超越 BMD
  • 批准号:
    8043597
  • 财政年份:
    2009
  • 资助金额:
    $ 15.7万
  • 项目类别:
Age Related Bone Loss Assessed by Ultrasound Tomography: Bone Quality Beyond BMD
通过超声断层扫描评估与年龄相关的骨质流失:骨质量超越 BMD
  • 批准号:
    7560242
  • 财政年份:
    2009
  • 资助金额:
    $ 15.7万
  • 项目类别:
Age Related Bone Loss Assessed by Ultrasound Tomography: Bone Quality Beyond BMD
通过超声断层扫描评估与年龄相关的骨质流失:骨质量超越 BMD
  • 批准号:
    7760096
  • 财政年份:
    2009
  • 资助金额:
    $ 15.7万
  • 项目类别:

相似海外基金

COOPERATIVE AGREEMENT WITH THE PAN AMERICAN HEALTH ORGANIZATION
与泛美卫生组织的合作协议
  • 批准号:
    9065935
  • 财政年份:
    2014
  • 资助金额:
    $ 15.7万
  • 项目类别:
COOPERATIVE AGREEMENT WITH THE PAN AMERICAN HEALTH ORGANIZATION
与泛美卫生组织的合作协议
  • 批准号:
    8788900
  • 财政年份:
    2014
  • 资助金额:
    $ 15.7万
  • 项目类别:
Cooperative Agreement with Pan American Health Organization (PAHO)
与泛美卫生组织(PAHO)的合作协议
  • 批准号:
    8732111
  • 财政年份:
    2010
  • 资助金额:
    $ 15.7万
  • 项目类别:
Cooperative Agreement with Pan American Health Organization (PAHO)
与泛美卫生组织(PAHO)的合作协议
  • 批准号:
    8145578
  • 财政年份:
    2010
  • 资助金额:
    $ 15.7万
  • 项目类别:
Cooperative Agreement with Pan American Health Organization (PAHO)
与泛美卫生组织(PAHO)的合作协议
  • 批准号:
    8529690
  • 财政年份:
    2010
  • 资助金额:
    $ 15.7万
  • 项目类别:
Cooperative Agreement with Pan American Health Organization (PAHO)
与泛美卫生组织(PAHO)的合作协议
  • 批准号:
    8333850
  • 财政年份:
    2010
  • 资助金额:
    $ 15.7万
  • 项目类别:
Cooperative Agreement with Pan American Health Organization (PAHO)
与泛美卫生组织(PAHO)的合作协议
  • 批准号:
    8542496
  • 财政年份:
    2010
  • 资助金额:
    $ 15.7万
  • 项目类别:
Cooperative Agreement with Pan American Health Organization (PAHO)
与泛美卫生组织(PAHO)的合作协议
  • 批准号:
    8140030
  • 财政年份:
    2010
  • 资助金额:
    $ 15.7万
  • 项目类别:
AMERICAN SAMOA AFFILIATED COLLABORATIVE PERFORMANCE AGREEMENT FOR TOBACCO CONTROL
美属萨摩亚附属烟草控制合作履约协议
  • 批准号:
    8450040
  • 财政年份:
    2009
  • 资助金额:
    $ 15.7万
  • 项目类别:
AMERICAN SAMOA AFFILIATED COLLABORATIVE PERFORMANCE AGREEMENT FOR TOBACCO CONTROL
美属萨摩亚附属烟草控制合作履约协议
  • 批准号:
    8054728
  • 财政年份:
    2009
  • 资助金额:
    $ 15.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了